Healthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice
|
|
- Horace Osborne
- 5 years ago
- Views:
Transcription
1 CONTINUING EDUCATION Healthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice GOAL To provide participants with current information about current blood pressure goals and effective use of antihypertensive agents to achieve these goals. TARGET AUDIENCE This activity is intended for physicians, medical directors, pharmacists, pharmacy directors, primary care physicians, and specialists in internal medicine and cardiology. EDUCATIONAL OBJECTIVES After completing this continuing education activity, the participant should be able to: Review JNC 7 treatment goals and NHANES data illustrating prevalence of uncontrolled treated hypertension. Discuss the economic burden on the healthcare system of uncontrolled hypertension and resulting endorgan damage. Explain the role of combination therapy in achieving JNC 7 goals. Describe the role of RAS inhibitors in combination antihypertensive therapy. CONTINUING MEDICAL EDUCATION ACCREDITATION The University of Cincinnati College of Medicine designates this activity for a maximum of 2 Category 1 credits toward the AMA Physician s Recognition Award. Each physician should claim only those hours that he/she actually spends in the educational activity. The University of Cincinnati College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor medical education for physicians. Release Date: September 1, Expiration Date: September 30, CONTINUING PHARMACY EDUCATION ACCREDITATION Medical World Communications Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEUs) under the ACPE universal program number of H04. Release Date: September 1, Expiration Date: September 1, FUNDING This program is supported by an unrestricted educational grant from Sankyo Pharma Inc. THE AMERICAN JOURNAL OF MANAGED CARE
2 CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation The University of Cincinnati College of Medicine designates this educational activity for a maximum of 2 Category 1 credits toward the AMA Physician s Recognition Award. Each physician should claim only those hours that he/she actually spends in the educational activity. The University of Cincinnati College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor medical education for physicians. Continuing Pharmacy Education Accreditation Medical World Communications Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEUs) under the ACPE universal program number of H04. Instructions After reading Healthcare Economics of Achieving JNC 7 Blood Pressure Goals in Clinical Practice, complete the program evaluation and select the 1 best answer to each of the following questions. A statement of continuing education hours will be mailed to those who successfully complete (with a minimum score of 70%) the examination at the conclusion of the program. 1. Ischemic heart disease mortality has been shown to increase linearly with age starting at systolic/diastolic blood pressures of: a) >110/>70 mm Hg b) >115/>75 mm Hg c) >120/>80 mm Hg d) >140/>90 mm Hg 2. Which of the following statements about the findings of the most recent National Health and Nutrition Examination Survey (NHANES) is true? a) The prevalence of hypertension in the United States has decreased. b) The prevalence of hypertension is greatest among Asian Americans. c) Control of hypertension has improved since the previous survey but remains low. d) Control of hypertension has remained the same since the previous survey. 3. Which of the following statements about blood pressure is true? a) Diastolic blood pressure typically increases until about age 50 and then remains the same or declines. b) Systolic blood pressure tends to decline with age. c) In persons >50 years of age, diastolic blood pressure is a better prognostic indicator than systolic blood pressure. d) If a person s blood pressure is normal at age 55, it is likely to remain so. 4. Which of the following is not a feature of the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)? a) It introduces the concept of lifetime risk. b) It emphasizes the importance of systolic blood pressure as a cardiovascular risk factor. c) It introduces a prehypertension category. d) It sets a blood pressure goal of <140/90 mm Hg for patients with diabetes or chronic kidney disease. 5. JNC 7 lists compelling reasons for specific classes of antihypertensive drugs. Diabetes is a compelling indication for all of the following except a(an): a) Thiazide diuretic b) Beta blocker c) Aldosterone antagonist d) Angiotensin AT 1 receptor blocker (ARB) 6. Which of the following is not a JNC 7 recommendation about drug therapy? a) Most patients with stage 1 hypertension should receive an angiotensin-converting enzyme (ACE) inhibitor as initial therapy. b) Most patients with stage 1 hypertension should receive a thiazide diurectic either alone or in combination with another agent. c) Comorbid conditions are an important consideration in selecting therapy. d) Combination therapy is often needed to get to goal blood pressure. 7. The most recent NHANES data show a hypertension control rate in the United States of 31%. The Healthy People 2010 goal is: a) 50% b) 75% c) 85% d) 95% 8. In 2004, the cost of hypertension in the United States was estimated to be: a) $14.0 billion b) $41.5 billion c) $55.5 billion d) $75.0 billion S228 THE AMERICAN JOURNAL OF MANAGED CARE SEPTEMBER 2005
3 CME/CE QUIZ 9. Antihypertensive therapy dramatically reduces cardiovascular morbidity and mortality. The State of Health Care Quality: 2004 report showed the greatest reduction in: a) Stroke b) Myocardial infarction c) Atrial fibrillation d) Heart failure 10. In a recent study of insured patients with diabetes and hypertension, the most frequently used antihypertensive agents were: a) Thiazide diuretics b) ACE inhibitors c) ARBs d) Beta blockers 11. Which of the following statements is true? a) The most recent NHANES data show considerable progress in controlling blood pressure in patients with diabetes. b) The majority of diabetic patients treated in specialized hypertension clinics achieve blood pressure goals. c) A study of patients treated in a hypertension clinic showed that it is more difficult to achieve goal blood pressure in patients with diabetes than in other hypertensive patients. d) In one study, treatment to goal blood pressure in patients with diabetes increased the cost of lifetime treatment. 12. Which of the following statements is false? a) Subjects with isolated diastolic hypertension are at greater risk of cardiovascular events than those with isolated systolic hypertension. b) The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial showed that it is more difficult to achieve goal systolic blood pressure than goal diastolic blood pressure. c) Systolic blood pressure is a major factor in renal outcomes. d) Even patients with blood pressure regarded as optimal may be at increased risk for cardiovascular disease. 13. In the Hypertension Optimal Treatment study, about were able to achieve a goal diastolic blood pressure of 80 mm Hg on monotherapy. a) 25% b) 35% c) 50% d) 65% 14. Which of the following statements about angiotensin II is false? a) It is the hormone chiefly responsible for the effects of the renin-angiotensin-aldosterone system. b) It acts as a growth factor. c) It is a potent vasodilator. d) It has indirect pressor effects. 15. Which of the following statements about ARBs is false? a) They have dose-dependent effects on blood pressure. b) About 50% of patients treated with ARB monotherapy achieve a diastolic blood pressure of < 90 mm Hg. c) They are more effective in controlling blood pressure when combined with a diuretic. d) The incidence of side effects with an ARB is similar to that with an ACE inhibitor. 16. In the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria study, about of patients who received the 300-mg/day dosage achieved normoalbuminuria. a) One quarter b) One third c) One half d) Two thirds 17. In the Losartan Intervention For Endpoint reduction in hypertension study: a) Blood pressure reduction was greater in the losartan group. b) Blood pressure reduction was greater in the atenolol group. c) Blood pressure reduction was similar in the 2 groups. d) The risk of stroke was greater in the losartan group. 18. The Valsartan Antihypertensive Long-term Use Evaluation showed that: a) Rapid reduction of blood pressure is associated with more favorable outcomes. b) Blood pressure reductions were similar in the losartan and amlodipine groups. c) There were significant differences in cardiac morbidity and mortality in the losartan and amlodipine groups. d) New-onset diabetes occurred more frequently in the losartan group. 19. In a comparison of the starting doses of 4 ARBs, more patients achieved the blood pressure goal of 140/90 mm Hg in the group treated with: a) Valsartan b) Olmesartan c) Irbesartan d) Losartan 20. Overall, clinical trials of ARBs have shown: a) Greater blood pressure lowering efficacy than ACE inhibitors. b) A higher incidence of side effects with ARBs than with ACE inhibitors. c) No significant differences in blood pressure lowering efficacy within the class. d) Both cardiovascular and renal target-organ protection. VOL. 11, NO. 7, SUP. THE AMERICAN JOURNAL OF MANAGED CARE S229
4 CME QUIZ & EVALUATION For Physicians CME TEST FORM Healthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice Please circle your answers: 1. a b c d 2. a b c d 3. a b c d 4. a b c d 5. a b c d 6. a b c d 7. a b c d 8. a b c d 9. a b c d 10. a b c d 11. a b c d 12. a b c d 13. a b c d 14. a b c d 15. a b c d 16. a b c d 17. a b c d 18. a b c d 19. a b c d 20. a b c d (PLEASE PRINT CLEARLY) Name/Degree Street City State/ZIP Daytime Phone Fax Sponsored by the University of Cincinnati for 2 hours of Category 1 CME credit. Release Date: September 1, 2005 Expiration Date: September 30, 2006 CME Activity Evaluation Answer Form Instructions: Testing and Grading Procedures 1. Each participant achieving a passing grade of 70% or higher on any examination will receive an official computer form stating the number of CME credits earned. This form should be safeguarded and may be used as documentatio n of credits earned. 2. Participants receiving a failing grade on any exam will be notified and permitted to take 1 reexamination at no cost. 3. All answers should be recorded on the answer form. 4. To receive credit certification electronically, please provide your address. Detach and mail or fax the test portion of this page to: University of Cincinnati, Office of CME, PO Box , Cincinnati, OH ; phone: ; fax: Please print clearly to ensure receipt of CME credit. To take the test on-line, please go to edu/cme. Activity Evaluation How long did it take you to complete this activity? minutes How well did this activity achieve its educational objectives? Very well Well Somewhat Not at all What overall grade would you assign this activity? A B C D Did this activity exhibit promotional bias for any pharmaceutical agents? Yes No Will you make changes in your practice as a result of information presented in this lesson? Yes No Proj A132 S230 THE AMERICAN JOURNAL OF MANAGED CARE SEPTEMBER 2005
5 CE QUIZ For Pharmacists ANSWER CARD INSTRUCTIONS Testing and Grading Procedures 1. Each participant achieving a passing grade of 70% or higher on any examination will receive an official computer form stating the number of CE credits earned. This form should be safeguarded and may be used as documentation of credits earned. 2. Participants receiving a failing grade on any exam will be notified and permitted to take 1 reexamination at no cost. 3. All answers should be recorded on the answer form. Please print clearly to ensure receipt of CE credit. 4. To receive credit certification electronically, please provide your address. Detach and mail completed exam form with your $10.00 payment to Pharmacy Times, 405 Glenn Drive, Suite 4, Sterling, VA ; or fax to Take the test online for FREE at and receive immediate grading and CE credits, and download your CE statement of credit. Please photocopy the test form for additional test takers. Medical World Communications Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEUs) under the ACPE universal program number of H04. The program is available for CE credit through September 1, Answer card and evaluation form for Pharmacists follow on page S232. VOL. 11, NO. 7, SUP. THE AMERICAN JOURNAL OF MANAGED CARE S231
6 CE EVALUATION For Pharmacists ANSWER CARD AND EVALUATION FORM Healthcare Implications of Achieving JNC 7 Blood Pressure Goals in Clinical Practice PROGRAM EVALUATION Please mark your level of agreement with the following statements. (4 = Strongly Agree; 0 = Strongly Disagree) 1) Met its stated objectives ) Was well organized ) Contributed to my knowledge ) Presented current and relevant information ) Presented information in a fairly balanced and noncommercial manner ) Offered information useful in my professional practice ) Provided new insights into contemporary pharmacy practice (PLEASE PRINT CLEARLY) Name/Degree Street City State/ZIP Daytime Phone Fax Check (payable to Pharmacy Times) Credit Card (check one) VISA MasterCard American Express SSN - - Credit Card Number Expiration Date Signature (REQUIRED) Sponsored by Medical World Communications Office of Continuing Professional Education for 2 contact hours (0.2 CEUs) of CE credit. Expiration Date: September 1, 2006 Detach and mail completed answer card and evaluation form with your $10.00 payment to: Pharmacy Times 405 Glenn Drive Suite 4 Sterling, VA Or take the quiz online for FREE at ANSWER CARD Please circle your answers: a a a a a a a a a a b b b b b b b b b b c c c c c c c c c c d d d d d d d d d d a a a a a a a a a a b b b b b b b b b b c c c c c c c c c c d d d d d d d d d d PROJ A132 S232 THE AMERICAN JOURNAL OF MANAGED CARE SEPTEMBER 2005
7 SUPPLEMENT POLICY STATEMENT Standards for Supplements to The American Journal of Managed Care All supplements to The American Journal of Managed Care are designed to facilitate and enhance ongoing medical education in various therapeutic disciplines. All Journal supplements adhere to standards of fairness and objectivity, as outlined below. Supplements to The American Journal of Managed Care will: I. Be reviewed by at least one independent expert from a recognized academic medical institution. II. Disclose the source of funding in at least one prominent place. III. Be free from editorial control exerted by personnel from the funding organization. IV. Disclose any existence of financial interests of supplement contributors to the funding organization. V. Use generic drug names only, except as needed to differentiate between therapies of similar class and indication. VI. Be up-to-date, reflecting the current (as of date of publication) standard of care. VII. Be visually distinct from The American Journal of Managed Care. VIII. Publish information that is substantially different in form and content from that of the accompanying edition of The American Journal of Managed Care. IX. Prohibit excessive remuneration for contributors and reviewers. X. Carry no advertising. Publisher s Note: The opinions expressed in this supplement are those of the authors, presenters, and/or panelists and are not attributable to the sponsor or the publisher, editor, or editorial board of The American Journal of Managed Care. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this supplement are not necessarily the same as indicated in the package insert for the product and may reflect the clinical experience of the authors, presenters, and/or panelists or may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
CME/CE QUIZ CME/CE QUESTIONS
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation The University of Cincinnati College of Medicine designates this educational activity for a maximum of 2 Category 1 credits toward
More informationCME/CE QUIZ CME/CE QUESTIONS
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation The University of Cincinnati College of Medicine designates this educational activity for a maximum of two (2) AMA PRA Category 1
More informationSleep Disorders and Excessive Sleepiness: Impact on Quality of Life
CME/CE POSTTEST Sleep Disorders and Excessive Sleepiness: Impact on Quality of Life CME Information Program Overview Excessive sleepiness is a complaint found in patients who experience sleepiness at unwanted
More informationImproving Asthma Care: An Update for Managed Care
n posttest n Improving Asthma Care: An Update for Managed Care Physician Continuing Medical Education Accreditation Statement This activity has been planned and implemented in accordance with the Essential
More information... CME/CPE QUIZ... CME/CPE QUESTIONS
CME/CPE QUESTIONS Continuing Medical Education Accreditation The Johns Hopkins University School of Medicine designates this educational activity for a maximum of 2 credit hours in category 1 credit toward
More informationCME/CE POSTTEST CME/CE QUESTIONS
CME/CE POSTTEST CME/CE QUESTIONS Controlling Asthma Severity: Identifying Unmet Needs and Optimizing Therapeutic Options There are no fees for participating in and receiving continuing medical education
More information... CPE/CNE QUIZ... CPE/CNE QUESTIONS
CPE/CNE QUESTIONS Continuing Pharmacy Education Accreditation The Virginia Council on Pharmaceutical Education is approved by the American Council on Pharmaceutical Education as a provider of continuing
More informationUnderstanding the Mechanisms to Maintain Glucose
n posttest n Understanding the Mechanisms to Maintain Glucose Homeostasis: A Review for Managed Care Instructions After reading Understanding the Mechanisms to Maintain Glucose Homeostasis: A Review for
More informationHypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Olmesartan/Amlodipine (Azor), Olmesartan/Amlodipine/ HCTZ (Tribenzor) Reference Number: CP.CPA.XX Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial See Important
More informationReduced Carbohydrate Intake May Lower Cardiovascular Risk CME
To Print: Click your browser's PRINT button. NOTE: To view the article with Web enhancements, go to: http://www.medscape.com/viewarticle/516977 This activity is supported by funding from WebMD. Reduced
More informationWOMEN S HEALTH FOR PRIMARY CARE. San Diego, California Hotel del Coronado August 10 13, 2017
WOMEN S HEALTH FOR PRIMARY CARE San Diego, California Hotel del Coronado August 10 13, 2017 Thursday, August 10th: 7:30 am 8:00 am Registration and Hot Breakfast 8:00 am 9:00 am Gynecology Abnormal Uterine
More informationDiabetes MAYER B. DAVIDSON, MD,* CO-EDITOR-IN-CHIEF; HENRY N. GINSBERG, MD, REVIEWER; TERRENCE F. FAGAN, MANAGING EDITOR; CHING-LING CHEN, PhD, WRITER
Professional Postgraduate Services Release Date: March 14, 2008 Valid Through: July 14, 2008 Sponsor This educational activity is a component of the National Diabetes Education Initiative (NDEI ), sponsored
More informationDiabetes-Related Quality Measure Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials
Publishing Staff Senior Vice President of Clinical Affairs Jeff D. Prescott, PharmD, RPh Senior Clinical Projects Manager Ida Delmendo Clinical Projects Manager Tara Petersen Project Christina Doong Quality
More informationScientific conclusions and detailed explanation of the scientific grounds for the differences from the PRAC recommendation
Annex I Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommendation 1
More informationCARDIOLOGY & PULMONOLOGY FOR PRIMARY CARE. Yosemite, California Tenaya Lodge at Yosemite September 21 23, 2018
CARDIOLOGY & PULMONOLOGY FOR PRIMARY CARE Yosemite, California Tenaya Lodge at Yosemite September 21 23, 2018 Friday, September 21st: 7:00 am 7:30 am Registration and Hot Breakfast 7:30 am 8:30 am Cardiology
More informationCARDIOLOGY & PULMONOLOGY FOR PRIMARY CARE. Asheville, North Carolina The Omni Grove Park Inn May 18 20, 2018
CARDIOLOGY & PULMONOLOGY FOR PRIMARY CARE Asheville, North Carolina The Omni Grove Park Inn May 18 20, 2018 Friday, May 18th: 7:30 am - 8:00 am Registration and Hot Breakfast 8:00 am - 9:00 am Pulmonary
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationEFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION
EFFICACY & SAFETY OF ORAL TRIPLE DRUG COMBINATION OF TELMISARTAN, AMLODIPINE AND HYDROCHLOROTHIAZIDE IN THE MANAGEMENT OF NON-DIABETIC HYPERTENSION Khemchandani D. 1 and * Arif A. Faruqui 2 1 Bairagarh,
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Diovan, Diovan HCT, Exforge, Exforge HCT, Teveten) Reference Number: CP.HNMC.16 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important
More informationINTERNAL MEDICINE FOR PRIMARY CARE: CARDIOLOGY/INFECTIOUS DISEASE/NEUROLOGY/PULMONARY
INTERNAL MEDICINE FOR PRIMARY CARE: CARDIOLOGY/INFECTIOUS DISEASE/NEUROLOGY/PULMONARY Barcelona, Spain Majestic Hotel & Spa Barcelona May 25 28, 2015 Monday, May 25th: 7:30 am 8:00 am Registration and
More informationVA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005
VA/DoD Clinical Practice Guideline for the Diagnosis and Management of Hypertension - Pocket Guide Update 2004 Revision July 2005 1 Any adult in the health care system 2 Obtain blood pressure (BP) (Reliable,
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008
Irbesartan (Aprovel) for heart failure with preserved systolic function August 2008 This technology summary is based on information available at the time of research and a limited literature search. It
More informationACP Brief Fall 2006 prioritization. Angiotensin II Receptor Blockers (ARBs) for Proteinuria, Hypertension (HTN) and Congestive Heart Failure (CHF)
ACP Brief Fall 2006 prioritization Angiotensin II Receptor Blockers (ARBs) for Proteinuria, Hypertension (HTN) and Congestive Heart Failure (CHF) Background This topic was submitted by BC PharmaCare during
More informationClinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8. Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital
Clinical Updates in the Treatment of Hypertension JNC 7 vs. JNC 8 Lauren Thomas, PharmD PGY1 Pharmacy Practice Resident South Pointe Hospital Objectives Review the Eighth Joint National Committee (JNC
More informationEfficacy and safety of Olmesartan,Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension
Efficacy and safety of Olmesartan,Losartan, Valsartan, and Irbesartan in the Control of Essential Hypertension Done by :Meznah zaid Al-mutairi Pharm.D Candidate Princess Nora Bint Abdul Rahman University
More information2014 APPNA Florida Chapter Fall CME
Faculty Name: Asad Shaikh, MD ASSOCIATION OF PHYSICIANS OF PAKISTANI-DESCENT OF NORTH AMERICA CME Evaluation Presentation Title: Diagnosis and Prevention of Breast Cancer 2014 APPNA Florida Chapter Fall
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationCertification in Lower Extremity Geriatric Medicine Handbook
Certification in Lower Extremity Geriatric Medicine Handbook 555 8 th Ave, Ste 1902, New York, NY 10018 888 852 1442 1 Mission Statement We exist to protect and improve the podiatric health and welfare
More informationThe control of hypertension in the. Reaching for Aggressive Blood Pressure Goals: Role of Angiotensin Receptor Blockade in Combination Therapy REPORTS
REPORTS Reaching for Aggressive Blood Pressure Goals: Role of Angiotensin Receptor Blockade in Combination Therapy By Richard V. Milani, MD Abstract Elevated blood pressure, particularly systolic blood
More informationQuality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care
Quality ID #122: Adult Kidney Disease: Blood Pressure Management National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Intermediate
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationPart I Application- Route 4
2018 American Board of Oral Implantology/Implant Dentistry 211 East Chicago Avenue, Suite 750-B Chicago, Illinois 60611-2616 Phone: 312-335-8793 Fax: 312-335-9045 Part I Application- Route 4 First MI Last
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More informationNOTE: PODCAST/MP3 PROGRAM 1
PODCAST/MP3 PROGRAM 1 I N S T R U C T I O N S This program consists of a podcast/mp3 audio file and a printable PDF of the post-test that can be submitted for credit and/or used to assist learning. You
More informationDr. Khan Abul Kalam Azad Associate Professor Department of Medicine SZRMC, Bogra
Dr. Khan Abul Kalam Azad Associate Professor Department of Medicine SZRMC, Bogra Beta-blockers were used in several longterm morbidity and trials in the treatment of hypertension, either alone or in comparison
More informationStrategies for Managing Hypertension
Strategies for Managing Hypertension by Marsha K. Millonig, MBA, RPh President,Catalyst Enterprises, LLC E.L.F. Publications, Inc. is accredited by the Accreditation Council for Pharmacy Education as a
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationThe JNC 8 Guidelines: A Clinical Review
8 Osteopathic Family Physician (2015)1, 8-12 Osteopathic Family Physician, Volume 7, No. 1, January/February 2015 The JNC 8 Guidelines: A Clinical Review Gary Rivard, DO; Erik Seth Kramer, DO, MPH; Sean
More informationE & M Coding: Are You Leaving Money on the Exam Table?
ACS, PAHCOM & HNA Sponsored Practice Management Webcast Series March 2, 201 1 E & M Coding: Are You Leaving Money on the Exam Table? Introduction - Evaluation and Management Services (E&M Coding) are a
More informationARxCH. Annual Review of Changes in Healthcare. Entresto: An Overview for Pharmacists
Entresto: An Overview for Pharmacists David Comshaw, PharmD Candidate 2019 1 Gyen Musgrave, PharmD Candidate 2019 1 Suzanne Surowiec, PharmD, BCACP 1 Jason Guy, PharmD 1 1 University of Findlay College
More informationCardiovascular Update for the Primary Care Provider. Friday, June 12, 2015 Seattle
virginia mason continuing medical education Cardiovascular Update for the Primary Care Provider Friday, June 12, 2015 Seattle Faculty course director: J. Susie Woo, MD, FACC The Heart Institute at Virginia
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationII. Angiotensin Receptor Blockers (ARBs) Drug Class Review
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE DOD BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32 C.F.R. 199.21,
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More information2018 HEALTHCARE OUTCOMES PERFORMANCE SYMPOSIUM (HOPS) EVENT FACT SHEET
2018 HEALTHCARE OUTCOMES PERFORMANCE SYMPOSIUM (HOPS) EVENT FACT SHEET COURSE DESCRIPTION: This course is designed to offer orthopedic surgeons, allied health providers, and primary care providers comprehensive
More informationAngiotensin II Receptor Antagonists (ARBs), Renin Inhibitors, and Combinations Step Therapy Program Summary
OBJECTIVE The intent of the Angiotensin II Receptor Antagonists (ARBs), Renin Inhibitors, and Combinations Step Therapy (ST) program is to encourage use of cost-effective generic products - ACEIs, ACEI
More informationClinical Breakthroughs & Challenges In Hematologic Malignancies
Clinical Breakthroughs & Challenges In Hematologic Malignancies Saturday, January 19, 2013 Disney s Grand Floridian Resort Lake Buena Vista, Florida COURSE DIRECTOR CONFERENCE CONTACT Melissa.Pearson@Moffitt.org
More information7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
More informationNational Horizon Scanning Centre. Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation
Irbesartan (Aprovel) for prevention of cardiovascular complications in patients with persistent atrial fibrillation August 2008 This technology summary is based on information available at the time of
More informationBlood Pressure Targets: Where are We Now?
Blood Pressure Targets: Where are We Now? Diana Cao, PharmD, BCPS-AQ Cardiology Assistant Professor Department of Clinical & Administrative Sciences California Northstate University College of Pharmacy
More informationJNC-8. (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines
JNC-8 (Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure- 8) An Update on Hypertension Guidelines Derrick Sorweide, DO Assistant Professor of Family Medicine,
More informationFRONTLINE CARDIOLOGY. APRIL 21, 2018 College Park Marriott Hotel & Conference Center Hyattsville, MD COURSE DIRECTORS: COURSE CO-DIRECTOR:
2018 FRONTLINE CARDIOLOGY APRIL 21, 2018 College Park Marriott Hotel & Conference Center Hyattsville, MD COURSE DIRECTORS: Carolina I. Valdiviezo, MD COURSE CO-DIRECTOR: James C. Welsh, MD, MBA, MPH MedStar
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationClinical Policy: Angiotesin II Receptor Blockers and Renin Inhibitors Reference Number: CP.HNMC.15 Effective Date: Last Review Date: 08.
Clinical Policy: Reference Number: CP.HNMC.15 Effective Date: 11.16.16 Last Review Date: 08.17 Revision Log Line of Business: Medicaid Medi-Cal See Important Reminder at the end of this policy for important
More informationHypertension. Penny Mosley MRPharmS
Hypertension Penny Mosley MRPharmS Outline of presentation Introduction to hypertension Physiological control of arterial blood pressure What determines our bp? What determines the heart rate? What determines
More informationExcellence in Care: Advances in Diabetes Management
Excellence in Care: Advances in Diabetes Management Laura Abbey RN, BSN, MA, CDE INDEPENDENT STUDY Health Professions Institute for Continuing Education Austin Community College The Austin Community College
More informationGuideline scope Hypertension in adults (update)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Hypertension in adults (update) This guideline will update the NICE guideline on hypertension in adults (CG127). The guideline will be
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationPrevention of Heart Failure: What s New with Hypertension
Prevention of Heart Failure: What s New with Hypertension Ali AlMasood Prince Sultan Cardiac Center Riyadh 3ed Saudi Heart Failure conference, Jeddah, 13 December 2014 Background 20-30% of Saudi adults
More informationApril 8, The Edwin W. Monroe AHEC Conference Center 2000 Venture Tower Drive Greenville, North Carolina 27834
April 8, 2016 The Edwin W. Monroe AHEC Conference Center 2000 Venture Tower Drive Greenville, North Carolina 27834 Jointly Provided by: The Department of Internal Medicine, Division of Dermatology, The
More informationChapman University Digital Commons. Chapman University. Michael S. Kelly Chapman University,
Chapman University Chapman University Digital Commons Pharmacy Faculty Articles and Research School of Pharmacy 12-30-2016 Assessment of Achieved Systolic Blood Pressure in Newly Treated Hypertensive Patients
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 7 January 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 7 January 2009 LERCAPRESS 10 mg/10 mg, film-coated tablets Pack of 30 (CIP code: 385 953-3) Pack of 90 (CIP code:
More informationNATIONAL CERTIFICATE IN TOBACCO TREATMENT PRACTICE (NCTTP) TEST EXEMPTION OFFER APPLICATION VALID: OCTOBER 15, APRIL 15, 2018
NATIONAL CERTIFICATE IN TOBACCO TREATMENT PRACTICE (NCTTP) TEST EXEMPTION OFFER APPLICATION VALID: OCTOBER 15, 2017 - APRIL 15, 2018 I. Personal Information Name: Home Address: City: State/Province: Country:
More informationApril 5-10, Primary Care Medicine: Update Wailea Beach Marriott Hotel Maui, Hawaii
Division of General Internal Medicine Department of Medicine University of California, San Francisco, School of Medicine University of California San Francisco Primary Care Medicine: Update 2015 SUNDAY
More informationUpdate on Current Trends in Hypertension Management
Friday General Session Update on Current Trends in Hypertension Management Shawna Nesbitt, MD Associate Dean, Minority Student Affairs Associate Professor, Department of Internal Medicine Office of Student
More informationManaging hypertension: a question of STRATHE
(2005) 19, S3 S7 & 2005 Nature Publishing Group All rights reserved 0950-9240/05 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Managing hypertension: a question of STRATHE Department of Cardiovascular Disease,
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationNATIONAL CERTIFICATE IN TOBACCO TREATMENT PRACTICE (NCTTP) APPLICATION
NATIONAL CERTIFICATE IN TOBACCO TREATMENT PRACTICE (NCTTP) APPLICATION I. Personal Information Name: Home Address: City: State/Province: _ Country: Zip Code: _ Work Address: City: State/Province: _ Country:
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationALLHAT Investigators Report 10-Year Follow-up and Stand by Diuretics as First-Step Antihypertensive Treatment
1 sur 5 21/11/2009 07:26 www.medscape.com Medscape Medical News from the: American Heart Association (AHA) 2009 Scientific Sessions This coverage is not sanctioned by, nor a part of, the American Heart
More informationIn the Literature 1001 BP of 1.1 mm Hg). The trial was stopped early based on prespecified stopping rules because of a significant difference in cardi
Is Choice of Antihypertensive Agent Important in Improving Cardiovascular Outcomes in High-Risk Hypertensive Patients? Commentary on Jamerson K, Weber MA, Bakris GL, et al; ACCOMPLISH Trial Investigators.
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationPodcast/MP3 Instructions 1. Download the Podcast or MP3 audio file to your player. 2. Listen to the presentation. 3. To receive continuing education
Podcast/MP3 Instructions 1. Download the Podcast or MP3 audio file to your player. 2. Listen to the presentation. 3. To receive continuing education credit, use the link to the online test or print the
More informationExecutive Summary. Different antihypertensive drugs as first line therapy in patients with essential hypertension 1
IQWiG Reports Commission No. A05-09 Different antihypertensive drugs as first line therapy in patients with essential hypertension 1 Executive Summary 1 Translation of the executive summary of the final
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationPrimary Care Medicine: Update 2019
division of General Internal Medicine department of Medicine University of California San Francisco School of Medicine Primary Care Medicine: Update 2019 Sunday - Friday April 7-12, 2019 Wailea Beach Marriott
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 RASILEZ HCT 150 mg/12.5 mg, film-coated tablets B/30 (CIP code: 392 151-6) RASILEZ HCT 150 mg/25 mg, film-coated
More informationControversies Innovations
& in Transplantation Controversies Innovations Saturday, October 18, 2014 12:30 4:30 pm (lunch served from 11:30 am) The Queen s Conference Center Honolulu, Hawaii About the Conference Organ transplantation
More informationManagement of Atrial Fibrillation in Friday, October 6, 2017 Seattle
virginia mason continuing medical education Friday, October 6, 2017 Seattle Faculty course directors: Christopher L. Fellows, MD, FACC, FHRS Section Head, Cardiology Robert W. Rho, MD, FACC, FHRS J. Susie
More informationHypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015
Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor
More informationWhat in the World is Functional Medicine?
What in the World is Functional Medicine? An Introduction to a Systems Based Approach of Chronic Disease Meneah R Haworth, FNP-C Disclosure v I am a student of the Institute for Functional Medicine. They
More informationHealth Delivery and Technology in Today s DIABETES CARE
Health Delivery and Technology in Today s DIABETES CARE Applying Evidence Based Treatments to Personalized Care The Inn at St. John s. Plymouth, MI The 2018 Diabetes Care conference is sponsored by Grand
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationECHOCARDIOGRAPHY: MERGING PAST, PRESENT AND FUTURE October 3rd, 2015
ECHOCARDIOGRAPHY: MERGING PAST, PRESENT AND FUTURE October 3rd, 2015 A comprehensive review of practical applications for echocardiography. Doubletree Hotel 101 Mall Blvd Monroeville Pa, 15146 Course Director
More informationClinical Policy: ACEI and ARB Duplicate Therapy Reference Number: CP.PMN.61 Effective Date: Last Review Date: 05.18
Clinical Policy: Reference Number: CP.PMN.61 Effective Date: 08.01.14 Last Review Date: 05.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationHeart, Lung, Vascular Update for Primary Care Providers
CALL FOR EXHIBITORS Heart, Lung, Vascular Update for Primary Care Providers Friday-Saturday, September 5-6, 2014 UT Conference Center Knoxville, Tennessee Jointly-Provided by The University of Tennessee
More informationEchocardiography Update
Please join us for CVI s 3rd Annual Echocardiography Update Assessment of Diastolic Heart Disease Sunday, January 16, 2011 7:30 a.m. 3:45 p.m. Loews Philadelphia Hotel 1200 Market Street Philadelphia,
More informationIntegrating Devices. Pharmacotherapy
Fifth Annual New Frontiers in Heart Failure Therapy Integrating Devices & Pharmacotherapy Saturday, January 22, 2005 7:30AM 5:00PM 301 Park Avenue at East 49th Street New York, NY Jointly Sponsored by
More informationHypertension: JNC-7. Southern California University of Health Sciences Physician Assistant Program
Hypertension: JNC-7 Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! Reference Card
More informationHypertension. Most important public health problem in developed countries
Hypertension Strategy for Continued Success in Treatment for the 21st Century November 15, 2005 Arnold B. Meshkov, M.D. Associate Professor of Medicine Temple University School of Medicine Philadelphia,
More informationAmerican Physical Therapy Association Credentialed Clinical Instructor Program
American Physical Therapy Association Credentialed Clinical Instructor Program Co-sponsored by: University of Wisconsin-La Crosse Physical Therapy Program & American Physical Therapy Association Thursday,
More informationLayered Approaches to Studying Drug Responses
Layered Approaches to Studying Drug Responses Brian B Hoffman, MD Chief of Medicine VA Boston Health Care System Professor of Medicine Harvard Medical School Conflict of Interest: US Federal Grant Funding
More informationAmlodipine/olmesartan (Azor ) is indicated for the treatment of hypertension, alone or in combination with other antihypertensive medications.
Page 1 of 8 Policies Repository Policy Title Policy Number Oral Antihypertensive Agents FS.CLIN.9 Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on product
More information